CRANBURY, N.J. - Palatin Technologies (NYSE:PTN), Inc. (NYSE American: PTN), a small-cap biotech company with a market capitalization of $20.4 million, has announced its corporate milestones for ...

Palatin Technologies reported its Q2 FY2025 earnings, revealing a mixed financial performance but a significant stock price surge. The company posted an earnings per share (EPS) of -0.12, beating ...

Palatin Technologies Announces Pricing of up to $23 Million Public Offering Palatin Technologies Announces Pricing of up to $23 Million Public Offering. PR Newswire. CRANBURY, N.J., May 7, 2025.

Palatin is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific ...

--Palatin Technologies, Inc., a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system ...

Findings highlight PL9654 and PL9655's potential to treat diabetic retinopathy through inflammation resolution, vascular stabilization, and neuroprotection PL9654 and PL9655 down-regulate ...

Palatin Technologies (PTN) stock plunged 40% Wednesday after the company said a Phase 3 pivotal study for its drug PL9643 failed to meet a co-primary endpoint. Read more here.

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system ...

Statements in this press release that are not historical facts, including statements about future expectations of Palatin Technologies, Inc., such as statements about Palatin products in ...